Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (7)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Emery, P.
Right arrow Articles by Williams, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Emery, P.
Right arrow Articles by Williams, B.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Rheumatology 1999; 38: 911-912
© 1999 British Society for Rheumatology

Editorials

Targeted therapies in rheumatoid arthritis: the need for action

P. Emery, G. Panayi1, R. Sturrock2 and B. Williams3

Rheumatology and Rehabilitation Research Unit, University of Leeds, 36 Clarendon Road, Leeds LS2 9NZ,
1 Department of Rheumatology, UMDS, Guy's Hospital, London SE1 9RT,
2 Centre for Rheumatic Diseases, University Department of Medicine, Glasgow Royal Infirmary and
3 Department of Rheumatology, University of Wales, Cardiff, UK

Rheumatoid arthritis (RA) is a common, chronic, disabling disease with a significant morbidity and mortality; the reduction of life expectancy is estimated at up to 10 yr. The total cost of the disease has been calculated at over 1 billion pounds per annum in the UK.

Over the last 20 yr, insights into the understanding of the pathogenesis of RA have been one of the brightest jewels in the biomedical crown. It is generally agreed that antigenic peptides, presented in the groove of the HLA-DR4 antigen, stimulate CD4+ T cells. These, in turn, activate macrophages, B cells . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 BMJHome page
P. Emery and M. Buch
Treating rheumatoid arthritis with tumour necrosis factor alpha blockade
BMJ, February 9, 2002; 324(7333): 312 - 313.
[Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
P. Geborek, T. Saxne, P. Emery, G. Panayi, R. D. Sturrock, and B. D. Williams
Clinical protocol for monitoring of targeted therapies in rheumatoid arthritis
Rheumatology, October 1, 2000; 39(10): 1159 - 1161.
[Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
S. Bingham and P. Emery
Resistant rheumatoid arthritis clinics-- a necessary development?
Rheumatology, January 1, 2000; 39(1): 2 - 5.
[Full Text] [PDF]